IO Biotech
IOBT
IOBT was delisted on the 6th of April, 2026.
18 hedge funds and large institutions have $47.4M invested in IO Biotech in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 18 → 18 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
3.06% less ownership
Funds ownership: 44.63% → 41.57% (-3.1%)
14% less capital invested
Capital invested by funds: $55.3M → $47.4M (-$7.84M)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$546K |
| 2 |
Renaissance Technologies
New York
|
+$136K |
| 3 |
MG
Marex Group
London,
|
+$78.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$35.7K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$27.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.62M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.14M |
| 3 |
AC
Armistice Capital
New York
|
-$347K |
| 4 |
Morgan Stanley
New York
|
-$147K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$35.7K |
IOBT Hedge Fund Activity: Q1 2024 in Review
18 of the 6,962 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q1 2024, worth a combined $47.4M — down 14% from $55.3M a quarter earlier.
Fund positioning in IOBT was balanced in Q1 2024: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 5 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $546K. The largest seller was Stonepine Capital Management, cutting an estimated $2.62M.
- 18 institutional investors held IO Biotech (IOBT) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $47.4M of IO Biotech stock for Q1 2024, down 14% quarter-over-quarter.
- 3 funds opened new IO Biotech positions in Q1 2024 and 3 closed out, a net change of 0 holders.
- The largest IO Biotech buyer in Q1 2024 was Fidelity Investments, an estimated $546K added.
- The largest IO Biotech seller in Q1 2024 was Stonepine Capital Management, an estimated $2.62M sold.
Based on aggregated 13F filings for Q1 2024.